Position in ENGN
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$19,030
-$55,880 QoQ
Shares Held
11,000
0.0% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#54
of 60 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PFS Partners, LLC holds $1,629,815 across 9 Biotechnology names. ENGN ranks #4 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
79,000 | $1,473,350 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
158 | $78,483 | |
| 3 | AVTX |
Avalo Therapeutics, Inc.
|
2,000 | $36,960 | |
| 4 | ENGN |
enGene Therapeutics Inc.
This page
|
11,000 | $19,030 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
24 | $14,964 | |
| 6 | TECH |
BIO-TECHNE Corp
|
67 | $4,733 | |
| 7 | PRQR |
ProQR Therapeutics N.V.
|
1,000 | $1,860 | |
| 8 | EXEL |
Exelixis, Inc.
|
8 | $435 |
All Filings in ENGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,030 | 11,000 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $74,910 | 11,000 | Shares | Sole | 2026-04-09 | |
| 2025-12-31 | $99,330 | 11,000 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $61,470 | 9,000 | Shares | Sole | 2025-10-16 | |
| No filing history on record for this holder in this stock. | ||||||